摘要
肿瘤坏死因子(TNF)超家族(TNFSF)包括有关三十个结构相关的受体(TNFSFRs)和绑定到一个或多个这些受体的大约二十个蛋白质配体。几乎所有这些细胞表面蛋白质相互作用(PPIs)代表高价值的治疗目标即自身免疫性疾病、移植受体、癌症的炎症反应和免疫调制,还有那些在临床开发的各个阶段的几种生物制剂包括抗体、融合蛋白定位。如果可以解决与小分子的蛋白质相互作用的目标相关的困难,小分子抑制剂或活化剂可以代表可能的替代品。化学合成证明了这种方法的可行性并以确定了大量的肿瘤坏死因子超家族受体-肿瘤坏死因子超家族型PPIs不同的药物研发途径包括CD40-CD40L、 BAFFR-BAFF、TRAIL-DR5和 OX40-OX40L。在此,对相应的结构、信号和药物化学方面简要综述。然而这些小分子调节剂没有到目前为止能确定似乎有足够的前景用于临床上。他们提供验证的证据表明,这些相互作用容易受到小分子调控作用的影响,可以作为识别更有效的和有选择性的备选项的出发点。
关键词: CD40,协同信号,成药性,OX40,肿瘤坏死因子。
图形摘要
Current Drug Targets
Title:TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation
Volume: 16 Issue: 4
Author(s): Yun Song and Peter Buchwald
Affiliation:
关键词: CD40,协同信号,成药性,OX40,肿瘤坏死因子。
摘要: The tumor necrosis factor (TNF) superfamily (TNFSF) contains about thirty structurally related receptors (TNFSFRs) and about twenty protein ligands that bind to one or more of these receptors. Almost all of these cell surface protein-protein interactions (PPIs) represent high-value therapeutic targets for inflammatory or immune modulation in autoimmune diseases, transplant recipients, or cancers, and there are several biologics including antibodies and fusion proteins targeting them that are in various phases of clinical development. Small-molecule inhibitors or activators could represent possible alternatives if the difficulties related to the targeting of protein-protein interactions by small molecules can be addressed. Compounds proving the feasibility of such approaches have been identified through different drug discovery approaches for a number of these TNFSFR-TNFSF type PPIs including CD40-CD40L, BAFFR-BAFF, TRAIL-DR5, and OX40-OX40L. Corresponding structural, signaling, and medicinal chemistry aspects are briefly reviewed here. While none of these small-molecule modulators identified so far seems promising enough to be pursued for clinical development, they provide proof-of-principle evidence that these interactions are susceptible to small-molecule modulation and can serve as starting points toward the identification of more potent and selective candidates.
Export Options
About this article
Cite this article as:
Yun Song and Peter Buchwald , TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation, Current Drug Targets 2015; 16 (4) . https://dx.doi.org/10.2174/1389450116666150223115628
DOI https://dx.doi.org/10.2174/1389450116666150223115628 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oral Agents in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Interactions of Sex Steroids with Mechanisms of Inflammation
Current Drug Targets - Inflammation & Allergy Analogs of the Sea Anemone Potassium Channel Blocker ShK for the Treatment of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Recent Applications of Chemiluminescence Assays in Clinical Immunology
Mini-Reviews in Medicinal Chemistry CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Treatment of Central Nervous System Involvement Associated with Primary Sjogrens Syndrome
Current Pharmaceutical Design Polyreactive Antibodies in Anti-HIV-1 Responses
Current Molecular Medicine Mesenchymal Stem Cells Induced In Vitro Generated Regulatory-T Cells: Potential Soldiers of Transplantation Biology
Current Biotechnology Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology Hot topic: Editorial [Therapeutic Potential of Peptide Motifs - Part IV] (Jean Claude Herve)
Current Pharmaceutical Design NF-κB Inhibitors for the Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Recent Patents on the Treatment of Type 1 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Role of C1858T Polymorphism of Lymphoid Tyrosine Phosphatase in Egyptian Children and Adolescents with Type 1 Diabetes
Current Diabetes Reviews Use of Synbiotics for Ulcerative Colitis Treatment
Current Clinical Pharmacology The Role of Transforming Growth Factor-β1 Gene Polymorphism and Its Serum Levels in Hashimoto’s Thyroiditis
Current Pharmaceutical Biotechnology Gut Inflammation: Current Update on Pathophysiology, Molecular Mechanism and Pharmacological Treatment Modalities
Current Pharmaceutical Design Generation of Regulatory T Cells to Antigen Expressed in the Retina
Current Immunology Reviews (Discontinued) Fragment-Based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction
Current Topics in Medicinal Chemistry